Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Treatment Resistant Depression
Interventions
CERC-501, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
Genetic · Drug
Lead sponsor
Vector Y Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Conditions
Anemia
Interventions
Salsalate, Placebo
Drug
Lead sponsor
Harvey Jay Cohen
Other
Eligibility
65 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
12
States / cities
Summerfield, Florida • Savannah, Georgia • Chicago, Illinois + 8 more
Conditions
Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
Interventions
Placebo, PIZV
Drug · Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
271 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
7
States / cities
Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Conditions
Rheumatoid Arthritis
Interventions
APLA12, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
HER2-positive Metastatic Breast Cancer
Interventions
Alpelisib, Tucatinib, Fulvestrant
Drug
Lead sponsor
Criterium, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Fort Collins, Colorado • New Orleans, Louisiana + 1 more
Conditions
Smoking Cessation
Interventions
Varenicline Tartrate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of IMR-687 in Healthy Adult Volunteers

NCT02998450
Conditions
Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
Interventions
IMR-687, Placebo Oral Capsule
Drug
Lead sponsor
Cardurion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Chronic Granulomatous Disease Transplant
Interventions
Alemtuzumab, Busulfan, Sirolimus, Cyclophosphamide, Total Body Irradiation, Peripheral blood stem cells
Drug · Radiation · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections
Interventions
Angiotensin 1-7
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Conditions
HIGH GRADE GLIOMA
Interventions
TH-302 preoperative, Placebo, TH-302 (escalating) with bevacizumab 10mg/kg
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Completed Phase 2 Interventional Results available

Oral Testosterone for the Treatment of Hypogonadism

NCT01717768
Conditions
Hypogonadism
Interventions
TSX-002
Drug
Lead sponsor
TesoRx Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

DARA RVD For High Risk SMM

NCT04775550
Conditions
High-risk Smoldering Multiple Myeloma, Multiple Myeloma
Interventions
Daratumumab, Bortezomib, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Omar Nadeem, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2030
U.S. locations
6
States / cities
Stamford, Connecticut • Boston, Massachusetts • Foxborough, Massachusetts + 2 more
Conditions
Venous Leg Ulcers
Interventions
Nexagon® Low Dose, Nexagon® High Dose, Nexagon® Vehicle
Drug
Lead sponsor
OcuNexus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 15 more
Conditions
Myelofibrosis
Interventions
Imetelstat 4.7 mg/kg, Imetelstat 9.4 mg/kg
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
29
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 26 more
Conditions
Extreme Prematurity
Interventions
Epo, Control
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
24 Weeks to 27 Weeks
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Glaucoma Drug Delivery System

NCT00824720
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
High Dose Device, Low Dose Device, Placebo Device
Drug · Device
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more
Completed Phase 1Phase 2 Interventional Results available

A Study of JR-171 in Patients With Mucopolysaccharidosis I

NCT04227600
Conditions
Mucopolysaccharidosis I
Interventions
JR-171 (lepunafusp alfa)
Drug
Lead sponsor
JCR Pharmaceuticals Co., Ltd.
Industry
Eligibility
0 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Conditions
Diabetes Mellitus, Type 2
Interventions
MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
22
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more
Conditions
Malignant Glioma of Brain, Astrocytoma, Malignant Astrocytoma, Oligodendroglioma, Anaplastic Oligodendroglioma of Brain (Diagnosis), Mixed Oligo-Astrocytoma, Ependymoma, Ganglioglioma, Pylocytic/Pylomyxoid Astrocytoma, Brain Tumor, Glioma, Brain Cancer, Glioblastoma, Glioblastoma Multiforme
Interventions
rQNestin, Cyclophosphamide, Stereotactic biopsy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
5
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more
Conditions
Hypertrophy, Left Ventricular
Interventions
carvedilol MR, atenolol, lisinopril
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
78
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more